COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

UC San Diego Division of Regenerative Medicine Research

Division Faculty Ongoing Research

Dr. Jamieson specializes in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies. Jamieson Lab Research
The Kaufman laboratory uses human pluripotent stem cells to understand the development of blood cells (both hematopoietic stem cells and functional lymphocytes: T cells and NK cells) and related mesodermal cell populations (including bone, endothelial and smooth muscle/vascular cells). The aim is to use human pluripotent stem cells as a resource to produce blood and immune cells for new clinical applications for treatment of relapsed/refractory cancers -- both hematologic malignancies and solid tumors. Kaufman Lab Research
The Signer Laboratory investigates stem cells at the interface of regenerative medicine and cancer biology. Stem cells have the remarkable potential to regenerate many of the specialized cells in our bodies after they are lost to normal wear and tear, injury and disease. Declines in stem cell function can lead to the onset of degenerative diseases. By unlocking the mysteries of stem cells, we expect to make breakthroughs that allow us to harness the regenerative potential of stem cells to treat degenerative diseases and identify new therapeutic targets to eradicate cancer.​ Signer Lab Research
The research in the Crews Lab aims to investigate the function of cancer stem cells in multiple myeloma progression and relapse. Collaborating with the Jamieson lab, they have identified a role for inflammation responsive pathways in the acquisition of drug resistance and stem cell-like behavior of malignant cells in multiple myeloma. Dr. Crews is also pioneering novel myeloma stem cell-targeted RNA detection tools with the overall goal of developing new regenerative medicine technologies that will improve the diagnosis and treatment of a variety of human cancers and other age-related disorders. Crews Lab Research
The goals of the Rich Lab are to identify novel therapeutic paradigms in the treatment of advanced cancers, primarily malignant brain tumors, through the understanding of a stem cell-like phenotype found in many cancers and core signal transduction pathways amenable to pharmacologic targeting.  The aim is to better understand the clinical relevance of cancer stem cells and the interaction with the tumor microenvironment and underlying genetic driver mutations in human cancers. Rich Lab Research